ITPR2 (Inositol 1,4,5-trisphosphate Receptor Type 2) is a large intracellular calcium release channel located primarily on the endoplasmic reticulum (ER) membrane. As a member of the IP3 receptor family, ITPR2 plays a fundamental role in cellular signaling by mediating the release of calcium ions from ER stores in response to various extracellular and intracellular stimuli[1].
Calcium signaling is essential for numerous neuronal functions including synaptic transmission, gene expression, mitochondrial function, and cellular survival. Dysregulation of calcium homeostasis is a hallmark of many neurodegenerative diseases, making ITPR2 a critical protein in understanding the molecular basis of neurodegeneration[2].
ITPR2 is a massive ~3000 amino acid protein forming a tetrameric channel complex. Each subunit contains:
The IP3 binding domain comprises a "armadillo repeat" fold that undergoes conformational changes upon IP3 binding, leading to channel opening. The channel pore is formed by the six transmembrane helices with a selectivity filter determining ion specificity. The C-terminal tail contains a calcium-binding EF-hand domain that modulates channel activity in response to intracellular calcium concentrations.
ITPR2 functions as a ligand-gated calcium release channel:
ITPR2 activity is modulated by multiple factors:
Calcium dysregulation is an early feature of Alzheimer's disease pathogenesis. ITPR2 contributes to AD through several mechanisms[3]:
Dopaminergic neurons exhibit specific vulnerabilities related to calcium signaling[4]:
In ALS, ITPR2 dysfunction contributes to motor neuron degeneration[5]:
ITPR2 alterations have been documented in HD models[6]:
Modulating ITPR2 activity represents a therapeutic strategy:
Therapeutic targeting of ITPR2 is complicated by:
Bezprozvanny, I. (2009). Calcium signaling and neurodegenerative diseases. Cell Calcium. 2009. ↩︎
Mattson, M.P. (2012). Calcium and neurodegeneration. Aging Cell. 2012. ↩︎
Stalford, S.A. et al. (2021). IP3 receptor heterogeneity and Alzheimer's disease. Neurobiology of Aging. 2021. ↩︎
Berridge, M.J. (2012). Calcium signalling in Parkinson's disease. Cell Calcium. 2012. ↩︎
Gomez, R. et al. (2016). IP3R-mediated ER-mitochondria calcium dysregulation in ALS. Cell Reports. 2016. ↩︎
Haghighi, M. et al. (2020). ER calcium depletion in Huntington's disease. Journal of Huntington's Disease. 2020. ↩︎